Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCM-010 in Secondary Progressive Multiple Sclerosis
NCT03696485Phase 2Withdrawn
- Sponsor
- Stem Cell Medicine
- Start
- Feb 2024
- Primary completion
- Feb 2025
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
A Phase 2 trial of SCM-010 in secondary-progressive multiple sclerosis (SPMS), sponsored by Stem Cell Medicine. Planned start Feb 2024; status: withdrawn.
02
Drugs
SCM-010
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT03696485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03696485.